Desmond Curran is currently employed as Senior Director, Vaccines Global Value Evidence and Outcomes Portfolio Lead at GlaxoSmithKline. He has more than 20 years’ experience in medical research having worked in a non-profit research organization (European Organisation for Research and Treatment of Cancer (EORTC)), a contract research organization (ICON Clinical Research), and for a pharmaceutical company (GlaxoSmithKline). Desmond completed his PhD in patient reported outcomes while working at the EORTC. He has authored approximately 100 peer reviewed published manuscripts, contributed book chapters in topics such as patient reported outcomes (PROs) and cancer research. Desmond led the GSK vaccines value evidence team supporting the launch of Shingrix, the recombinant zoster vaccine. Desmond’s key areas of expertise include: health economics; patient reported outcomes; value demonstration; real world evidence; pricing & market access; health technology assessment; biostatistics and clinical trial design.
Impact of respiratory syncytial virus infection on quality of life in adults aged ≥50 years: A qualitative patient experience study
Desmond Curran, GSK, Belgium
Benjamin Bracke, GSK, Belgium
Philibert Goulet, GSK, Belgium
John H. Powers III, George Washington University School of Medicine, United States
Respiratory syncytial virus (RSV) affects almost all children by age 2. Reinfection is common for individuals aged ≥50 years. However, patient experience and impact of RSV on quality of life remains scarcely documented.
Characterization of patient experience and burden of RSV disease in adults aged ≥50 years in the United States to develop a conceptual model, visually representing signs, symptoms, and functional impacts of RSV.
Thirty adults aged ≥50 years participated in this qualitative, non-interventional, cross-sectional study between January and March 2020. They had polymerase chain reaction confirmed diagnoses of RSV acute respiratory infection within six months of recruitment. Webcam or telephone interviews were conducted by trained qualitative researchers using a semi-structured interview guide. Concept elicitation information was coded and analyzed using NVivo software to identify important elements of RSV disease experience.
A total of 30 qualitative interviews were conducted (50% male) in three age groups: 50-64 years (n=15), 65-79 years (n=12) and ≥80 years (n=3). Eighteen had co-morbidities such as asthma and chronic obstructive pulmonary disease. Twenty were interviewed within two months since the RSV episode, five within three months and five within six months. Twenty-two (73%) had received outpatient treatment and eight (27%) hospital/emergency room treatment. All participants reported impacts on daily activities during RSV disease. Most (24/30) could not leave the house. All reported impacts on social activities and relationships; 26/30 described avoiding others and 25/30 cancelled social plans. Physical functioning was impaired in 25/30 participants, and 18/30 reported not engaging in leisure activities or hobbies. All nine working participants reported major impacts on work. Sleep disruptions at night were reported by 22/30 participants. Most participants (28/30) described emotional impacts. These were unsolicited reports and are therefore likely to be underestimated, as this study objective was to identify important concepts rather than to measure frequency. Symptoms such as trouble breathing and vomiting were particularly concern-raising for participants. Some participants aged >65 years or with exacerbations of existing conditions due to RSV infection described fear of dying or returning to hospital. Many participants (19/30) reported symptoms that lingered beyond the acute disease stage from a week to >1 month. These impacts were used to develop a conceptual model.
RSV infection in adults aged ≥50 years had significant impact on daily life, including productivity inside and outside the home, social and leisure activities, relationships and emotional functioning, physical functioning, vitality and sleep.